Jessamy C. Tiffen

Jessamy C. Tiffen

Missenden Road
Camperdown, NSW 2050, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications

X and Y Differences in Melanoma Survival Between the Sexes.

X and Y Differences in Melanoma Survival Between the Sexes.

Journal: Pigment cell & melanoma research
Published: February 05, 2024

BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment.

BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment.

Journal: Pigment cell & melanoma research
Published: December 18, 2023

Correction: Overexpression of VIRMA confers vulnerability to breast cancers via the m6A-dependent regulation of unfolded protein response.

Correction: Overexpression of VIRMA confers vulnerability to breast cancers via the m6A-dependent regulation of unfolded protein response.

Journal: Cellular and molecular life sciences : CMLS
Published: July 14, 2023

Overexpression of VIRMA confers vulnerability to breast cancers via the m6A-dependent regulation of unfolded protein response.

Overexpression of VIRMA confers vulnerability to breast cancers via the m6A-dependent regulation of unfolded protein response.

Journal: Cellular and molecular life sciences : CMLS
Published: February 06, 2023

Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7.

Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7.

Journal: Cellular and molecular life sciences : CMLS
Published: March 24, 2022

Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells.

Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells.

Journal: Cancers
Published: December 16, 2021

Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma.

Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma.

Journal: The Journal of investigative dermatology
Published: June 22, 2021

Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers.

Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers.

Journal: Frontiers in genetics
Published: March 15, 2021

Sex bias of females in survival from cancer and infections. Is X the answer?

Sex bias of females in survival from cancer and infections. Is X the answer?

Journal: British journal of cancer
Published: November 12, 2020

A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma.

A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma.

Journal: The Journal of investigative dermatology
Published: October 01, 2020

Study of the Female Sex Survival Advantage in Melanoma-A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts.

Study of the Female Sex Survival Advantage in Melanoma-A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts.

Journal: Cancers
Published: June 26, 2020

Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma?

Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma?

Journal: Pigment cell & melanoma research
Published: November 27, 2019
Showing 1-12 of 37

Last Updated: 09/26/2026